Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-I… (NCT07729670) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC
42 participantsStarted 2026-06
Plain-language summary
This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with pathologically confirmed resectable stage II-IIIB (N2) non-small cell lung cancer (NSCLC).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age \>= 18 years, either gender;
* Pathologically confirmed stage II-IIIB (N2) squamous or non-squamous non-small cell lung cancer (NSCLC) according to the 9th edition of the AJCC/UICC NSCLC staging system;
* Presence of lesions suitable for ablation therapy confirmed by imaging evaluation;
* Evaluated as resectable with R0 resection before enrollment, and consent to undergo radical surgical resection;
* ECOG performance status score of 0-1;
* Eligible for platinum-based doublet chemotherapy;
* Adequate cardiopulmonary function to meet the requirements of curative surgical resection;
* Sufficient organ function confirmed by laboratory tests within 28 days before enrollment:
* Blood routine: WBC \>= 3.0×10\^9/L; ANC \>= 1.5×10\^9/L; PLT \>= 100×10\^9/L; HGB \>= 90 g/L.
* Liver function: AST \<= 5.0×ULN; ALT \<= 5.0×ULN; TBIL \<= 1.5×ULN;
* Renal function: Cr \<= 1.5×ULN;
* For patients receiving cisplatin: creatinine clearance \>= 60 mL/min.
* For patients receiving carboplatin: creatinine clearance \>= 45 mL/min.
* Coagulation function: INR \<= 1.5×ULN (\<=3×ULN for patients on anticoagulants; anticoagulants must be discontinued for one week before ablation); APTT \<= 1.5×ULN;
* Fully understand the study and voluntarily sign the informed consent form (ICF).
Exclusion Criteria:
* Tumor is adjacent to the hilum, invades major blood vessels, or has contraindications for surgery;
* History of interstitial lung disease, non-infectious pneumon…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Pathological Complete Response Rate
Timeframe: Perioperative
Trial details
NCT IDNCT07729670
SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences